What changed: Adrenocortical carcinoma
Every dated change on the records linked to Adrenocortical carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Regulatory1Guideline2Milestone8This record1
September 2026 · 1
2023 · 1
2019 · 1
2018 · 2
- 2018GuidelineAdrenocortical carcinomaGuideline ESE/ENSAT 2018: Advanced, indolent
Mitotane monotherapy (target level 14-20 mg/L) with glucocorticoid replacement; local therapies (ablation, radiotherapy) for oligometastases.
- 2018GuidelineAdrenocortical carcinomaGuideline ESE/ENSAT guideline 2018: Localised (ENSAT I-III)
Open en bloc adrenalectomy by an experienced surgeon with locoregional lymphadenectomy; adjuvant mitotane for high-risk (Ki-67 >10%, stage III, R1) for 2-5 years; adjuvant radiotherapy for R1.